scispace - formally typeset
M

Md. Asaduzzaman Khan

Researcher at Central South University

Publications -  85
Citations -  2938

Md. Asaduzzaman Khan is an academic researcher from Central South University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 24, co-authored 70 publications receiving 2142 citations. Previous affiliations of Md. Asaduzzaman Khan include Southwest Medical University & University of Texas at Dallas.

Papers
More filters
Journal ArticleDOI

Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements.

TL;DR: The major issue is targeting the dual actions of ROS effectively with respect to the concentration bias, which needs to be monitored carefully to impede tumor angiogenesis and metastasis for ROS to serve as potential therapeutic targets exogenously/endogenously.
Journal ArticleDOI

Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer

TL;DR: This review summarizes the update information on the association of EMT-TFs with cancer metastasis and the possible cancer therapeutics via targeting the EMT -TFs.
Journal ArticleDOI

Anticancer activities of Nigella sativa (black cumin).

TL;DR: The molecular mechanisms behind its anticancer role is still not clearly understood, however, some studies showed that TQ has antioxidant role and improves body's defense system, induces apoptosis and controls Akt pathway.
Journal ArticleDOI

Antioxidant Enzymes and Cancer

TL;DR: This review article aims to further elucidate the relationship between antioxidant enzymes and cancers by summarizing the findings of some of the important study concerning expression levels and genetic polymorphisms of antioxidant enzymes in cancer patients.
Journal ArticleDOI

Thymoquinone, as an anticancer molecule: from basic research to clinical investigation

TL;DR: The potential of thymoquinone as anticancer molecule, its mechanism of action and future usage in clinical applications are discussed, and the optimum time to focus on clinical trials for developing thymosinone as a future drug in cancer therapeutics is now.